News that group development director Steve Lane has resigned to pursue other interests came as the latest in a long line of setbacks for beleaguered software developer Financial Objects. Lane's departure, after six years, came just a few weeks after the company admitted that one of its customers had decided to cancel its Activebank banking solution contract. Though not expected to affect the company's performance significantly in its own right, details of the cancellation came just as FO was attempting to regroup after a November profit warning. Back then management had cautioned that the difficult trading conditions noted during the first half were continuing. As a result of these problems, and a £1.7m write off against software development overruns, full year figures are now expected to fall 'significantly' below past market expectations. Interim losses had shown increased losses of £1.2m on revenues 17% lower at £5.7m. Despite FO's woes a few positives remain, however. For one £7.1m remained in the bank at the end of October. For another the groups IBIS software division, from which more than 50% of all revenue is derived, continues to trade profitably. With analysts still forecasting a return to near breakeven in 2004 and the business itself (minus cash) currently valued at just £500,000, Financial Objects will rightly appeal to wealthy speculators. Everyone else should avoid for now.
Market cap: £7.6m
PE Forecast: n/a
Share price: 27p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.